Welander C E, Homesley H D, Reich S D, Levin E A
Department of Obstetrics & Gynecology, Bowman Gray School of Medicine, Winston-Salem, NC 27103.
Am J Clin Oncol. 1988 Aug;11(4):465-9. doi: 10.1097/00000421-198808000-00011.
Fourteen patients with relapsing ovarian cancer were treated with a regimen of intravenous interferon gamma (IFN gamma). During an initial induction phase, patients received 2 mg/m2 IFN gamma intravenously over 2 h daily for 5 days, repeated every 2 weeks for six courses. Patients who responded were continued on a maintenance phase, receiving 3 mg/m2 intravenously over 2 h, twice weekly every 2 weeks for 2 to 6 months. All patients had received prior cisplatin containing chemotherapy regimens. Of the 14 patients entered, 7 completed the six courses of the induction treatment. Four patients were clinical responders and continued on maintenance therapy. The most commonly reported toxicities included malaise, fever, and deteriorating performance status. There appears to be some clinically apparent antitumor activity demonstrated by this dosing schedule of interferon gamma in ovarian cancers.
14例复发性卵巢癌患者接受了静脉注射γ-干扰素（IFNγ）方案治疗。在初始诱导阶段，患者每天静脉注射2mg/m² IFNγ，持续2小时，共5天，每2周重复一次，共六个疗程。有反应的患者进入维持阶段，每2周静脉注射3mg/m²，持续2小时，每周两次，共2至6个月。所有患者之前均接受过含顺铂的化疗方案。14例入组患者中，7例完成了六个疗程的诱导治疗。4例患者为临床反应者并继续接受维持治疗。最常报告的毒性反应包括不适、发热和身体状况恶化。γ-干扰素的这种给药方案在卵巢癌中似乎显示出一些明显的临床抗肿瘤活性。
